Image Description (Celltrion Logo)
Memantine Hydrochloride
Product Images NDC 71335-1798
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 71335-1798). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Label (Lbl713351798)
Label for Memantine HCl 5mg Tablet by Bryant Ranch Prepack. The label states it is comparable to Namenda 5mg Tablet from Vivimed Life Sciences Pvt Ltd. The package contains 30 tablets. Storage instructions and a barcode are also visible. The product NDC is 71335-1798.*
Structure (Memantinehcltab Figure 01)
Chemical structure of Memantine Hydrochloride showing its molecular arrangement with labeled groups including NH2 and HCl, and methyl substitutions on the bicyclic ring system.*
Figure1 (Memantinehcltab Figure 02)
A line graph showing the mean change from baseline in ADCS-ADL score over 28 weeks of treatment. Two lines compare Placebo and Memantine HCl groups. The y-axis ranges from -7 to 2, indicating clinical decline to improvement, and the x-axis represents weeks of treatment at 0, 4, 12, and 28 weeks. Error bars show variability around the mean scores for each group.*
Figure2 (Memantinehcltab Figure 03)
A line graph comparing the cumulative percentage of patients versus ADCS-ADL change from baseline between Memantine Hydrochloride and placebo groups. The x-axis represents ADCS-ADL change values from 10 to -25, while the y-axis shows cumulative patient percentages from 0 to 100%. Two curves are shown: Memantine HCl (open circles) and placebo (black squares), with Memantine HCl generally showing greater change.*
Figure3 (Memantinehcltab Figure 04)
A line graph depicting mean change from baseline in SIB scores over 28 weeks of treatment comparing Placebo and Memantine Hydrochloride (MEMANTINE HCl). The vertical axis shows change with clinical improvement at the top and clinical decline at the bottom. Two lines represent Placebo (square markers) showing a decline and Memantine HCl (circle markers) showing a stable to slight improvement trend, each with error bars.*
Figure4 (Memantinehcltab Figure 05)
A cumulative percentage of patients graph showing SIB (Severe Impairment Battery) change from baseline on the horizontal axis and cumulative percentage of patients on the vertical axis. Two data series are shown: one for Placebo and one for Memantine Hydrochloride (MEMANTINE HCl), illustrating patient response distribution across SIB score changes.*
Figure5 (Memantinehcltab Figure 06)
A line graph showing the mean change from baseline in ADCS-ADL score over 24 weeks of treatment. The graph compares Memantine Hydrochloride/Donepezil with Placebo/Donepezil, indicating clinical improvement and decline, with error bars for SEM at each time point.*
Figure6 (Memantinehcltab Figure 07)
A cumulative percentage of patients chart comparing ADCS-ADL change from baseline between Placebo/Donepezil and Memantine HCl/Donepezil treatment groups. The X-axis represents ADCS-ADL change from baseline, and the Y-axis represents the cumulative percentage of patients. The chart shows two lines: one with squares for Placebo/Donepezil and one with circles for Memantine HCl/Donepezil.*
Figure7 (Memantinehcltab Figure 08)
A line graph depicting mean (± SEM) change from baseline in SIB score over 24 weeks of treatment, comparing Placebo/Donepezil and Memantine HCl/Donepezil groups. The Y-axis ranges from -4 to 4 with markers for clinical improvement and decline, showing separate trends for each group across weeks of treatment on the X-axis.*
Figure8 (Memantinehcltab Figure 09)
A cumulative percentage of patients graphed against SIB change from baseline, comparing treatment with Memantine HCl/Donepezil versus Placebo/Donepezil. The graph shows two curves, one marked with open circles for Memantine HCl/Donepezil and another with filled squares for Placebo/Donepezil, depicting patient response differences over a range of SIB score changes.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
